Sanofi and Orano Collaborate on Next-Gen Radioligand Medicines

Sanofi and Orano Med, a subsidiary of the Orano Group, are joining forces to advance the development of radioligand therapies for rare cancers. On October 17, 2024, the two companies announced their partnership to create a new entity under the Orano Med brand. This collaboration aims to accelerate the discovery, design, and clinical development of next-generation radioligand therapies (RLTs) utilizing lead-212 (212Pb) alpha-emitting isotopes. This follows Sanofi’s recent exclusive licensing agreement with Orano Med and RadioMedix to focus on late-stage radioligand therapies, specifically targeting rare cancers through AlphaMedix™.

Radioligand therapies combine the cancer-targeting capabilities of biological vectors with the potent, localized cell-destroying power of alpha-emitting radioisotopes. These therapies aim to deliver radioactive isotopes directly to cancer cells, which express specific markers, even if they have metastasized. The precision of this approach seeks to destroy cancer cells while minimizing damage to healthy cells, potentially revolutionizing treatment for some rare cancers and improving patients' longevity and quality of life.

Paul Hudson, CEO of Sanofi, expressed excitement about the partnership, emphasizing the collaboration as a pioneering move in France that brings together expertise in biopharma and nuclear technology. Hudson highlighted Sanofi’s commitment to fostering innovation in France and globally, aiming to develop cutting-edge treatments for cancer patients.

Nicolas Maes, CEO of Orano Group, noted that Orano Med’s success showcases the group's ability to diversify beyond its core nuclear business. By leveraging nuclear materials for targeted alpha therapies, Orano demonstrates that nuclear technology can positively impact society beyond energy and climate solutions, extending into human health. This innovation aligns with Orano’s dedication to exploring new opportunities and addressing significant global challenges.

Sanofi’s investment will fortify Orano Med, enabling the company to expedite the development of its lead-212 based therapies. Orano Med has established a unique global industrial platform, ensuring a reliable and scalable supply of these therapies through its vast stock of raw materials and patented manufacturing processes.

Houman Ashrafian, Executive Vice President and Head of Research and Development at Sanofi, expressed enthusiasm for investing in radioligand therapies, viewing it as a promising field for patients with rare cancers. Sanofi sees immense potential in Orano Med’s lead-212 based technologies, aligning with their commitment to pioneering transformative therapies for unmet medical needs.

Julien Dodet, President of the Governing Board at Orano Med, stated that Sanofi’s partnership validates Orano Med's strategy and reinforces its leadership in targeted alpha therapies. Dodet looks forward to combining Sanofi’s expertise with Orano Med’s research and development capabilities to advance treatments like AlphaMedix, aiming to make these transformative therapies accessible to patients swiftly.

Sanofi continues to prioritize oncology innovation, focusing on difficult-to-treat cancers, including rare cancers such as multiple myeloma, acute myeloid leukemia, lymphomas, and certain gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris Saclay Cancer Cluster and aim to contribute to the France 2030 plan’s ambitious oncology innovation agenda.

The agreement between Sanofi and Orano Med requires standard regulatory approvals. Under the agreement, Sanofi will make a €300 million equity investment, acquiring approximately 16% equity stake in the new entity valued at €1.9 billion.

Sanofi is a global healthcare company dedicated to advancing medical science and providing life-changing treatments. Orano Med is a clinical-stage biotechnology subsidiary of the Orano Group, specializing in developing targeted therapies against cancer using lead-212. Orano Group is renowned for its expertise in nuclear materials, addressing global energy and health challenges.